Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Rock Springs Capital Management LP

Rock Springs Capital Management LP raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 256,200 shares of the biopharmaceutical company's stock after purchasing an additional 6,200 shares during the period. Alnylam Pharmaceuticals accounts for approximately 2.3% of Rock Springs Capital Management LP's portfolio, making the stock its 12th largest holding. Rock Springs Capital Management LP owned approximately 0.20% of Alnylam Pharmaceuticals worth $60,286,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Larson Financial Group LLC grew its holdings in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Versant Capital Management Inc raised its stake in Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 83 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,984 shares of company stock worth $16,864,347 over the last ninety days. 1.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ALNY shares. Needham & Company LLC reissued a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $280.00 to $328.00 in a report on Monday, March 24th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday. Royal Bank of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Finally, Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Stock Up 3.7 %

ALNY stock traded up $8.95 during mid-day trading on Friday, hitting $251.56. 835,531 shares of the company were exchanged, compared to its average volume of 877,672. The company has a market capitalization of $32.72 billion, a PE ratio of -115.93 and a beta of 0.30. The firm has a fifty day simple moving average of $247.37 and a 200 day simple moving average of $256.10. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a twelve month low of $143.00 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.